Cointime

Janpix

company

About

Janpix operates as an oncology-focused startup.

Highlights

Total Funding Amount
$22M $10M
Funding Rounds
2
Investors
1
Employee Profiles
6

Details

Last Funding Type
Series A
Last Funding Money Raised
$22M
Industries
App Discovery,Biotechnology,Therapeutics
Founded date
Jan 1, 2013
Number Of Employee
1 - 10
Operating Status
Active

Janpix is discovering and developing inhibitors of Signal Transducer and Activator of Transcription (“STAT”) proteins. Most members of this family of transcription factors have been known for some time and their relevance in certain cancers, in particular for STAT3 & STAT5, validated. Inhibiting the function of STAT proteins though has been very challenging thus far and Janpix developed new chemistry to address this complex problem.

Funding Rounds

Number of Funding Rounds
Total Funding Amount
2
$22M $10M
Janpix has raised a total of $22M $10M in funding over 2 rounds. Their latest funding was raised on Oct 7, 2020 from a Series B round.
Announced Date Round Money Raised Number of Investors Lead Investors Post Valuation
Oct 7, 2020 Series B $10M 1 Medicxi — Detail
Oct 11, 2017 Series A $22M 1 Medicxi — Detail

Investors

Number of Lead Investors
Number of Investors
2
1
Janpix is funded by 1 investors. Medicxi are the most recent investors.
Investor Name Lead Investor Funding Round
Medicxi Yes Series B

Employee Profiles

Number of Employee Profiles
6
Janpix has 6 current employee profiles, including Board member Francesco Rubertis
Francesco Rubertis
Board member
Roman Fleck
Executive
Patrick T. Gunning
Executive
Giovanni Mariggi
Board member
Sanford Zweifach
Board member
Show More
Cointime
Content
Company